Cardiologist sues health system over gender discrimination, unequal pay and hostile treatment
The veteran doctor says she was treated “vastly different from her male counterparts” during her 17 years with Lehigh Valley Health Network.
Related Articles
First-ever data center on the Moon set to launch next month
Florida-based startup Lonestar Data Holdings plans to launch the first Moon-based data center dubbed the “Freedom Data Center.” The compact but fully operational information hub…
Cardiovascular disease and risk in COPD: a state of the art review
Chronic Obstructive Pulmonary Disease (COPD) and cardiovascular diseases (CVD) commonly co-exist. Outcomes of people living with both conditions are poor in terms of symptom burden,…
Trials in Women
Where do we start? Roxana Mehran hears from Noel Bairey Merz and Stefan Blankenberg.
Declining Trend of Sudden Cardiac Death in Younger Individuals: A 20-Year Nationwide Study | Circulation
BACKGROUND: Declining cardiovascular mortality rates have been well-documented, yet temporal trends of sudden cardiac death (SCD) in young individuals remain unclear. We provide contemporary nationwide…
NFL’s Las Vegas Raiders provide 12 schools with CPR resources to improve cardiac emergency outcomes
LAS VEGAS, January 24, 2025 — The American Heart Association and the Las Vegas Raiders gathered representatives from 12 local schools for cardiopulmonary resuscitation (CPR)…
ACKR1hiECs Promote Aortic Dissection Through Adjusting Macrophage Behavior | Circulation Research
BACKGROUND: Type A aortic dissection (TAAD) is a life-threatening condition characterized by complex pathophysiology, in which macrophages play a critical but not yet fully understood…
Valve durability after TAVR: Cardiologists track how deterioration influences outcomes
Researchers have made it a priority to learn as much about the durability of TAVR valves as possible. A new study in JACC: Cardiovascular Interventions…
Health researchers alarmed as Trump administration pauses travel, communications
The halt has frozen research grants, meetings and key health updates. “Everything is basically in chaos,” said one cancer researcher.
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation | NEJM
Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as…
